# Revolution Medicines, Inc.

**RVMDW**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001628171

# None

**No letter**

4 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $2.4B |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data, degenerate inputs<br>not computable: dilution, distress, fortress balance sheet |
| **Inputs computable** | 4 of 14 |
| **Graded from** | filings received through Feb 25, 2026<br>249 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026 |
| **Last close** | $10.22<br>2026-10-21; market equity $0; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 25, 2026*

We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Guided by our understanding of genetic drivers and adaptive resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 42.8** | | | | | | |
| Gross profitability | not computable | 32.4% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (9.5%) | (6.6%) | | 42.8 | 803 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 31.0** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | | |
| Altman Z double-prime | (0.01) | (0.35) | | 36.6 | 748 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *interest expense must exceed $100,000* | | | | | | |
| Current ratio | 7.14x | 2.92x | | 25.3 | 829 | 2025-12-31 |
| **Growth and financing, sleeve percentile 9.7** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *current value must be positive and the base must exceed $100,000* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *NOPAT must exceed $100,000* | | | | | | |
| Asset growth, three years | 42.6% | 2.2% | | 9.7 | 696 | 2025-12-31 |
| Net share issuance, one year | not computable | 2.5% | | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 4 of 14 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## What the price implies

*at the 2026-10-21 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 3,168.6% | (2.2%) | 100 |
| Distance from 52-week high | (26.0%) | (28.7%) | 54 |
| EBIT to enterprise value | not computable | (1.4%) | |
| Free cash flow yield | not computable | (1.0%) | |
| Book value to price | not computable | 0.28 | |
| Sales to price | not computable | 0.30 | |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | 3.32 | (0.19) | 100 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $815.4M |
| Operating cash flow, four quarters | -$1.2B |
| Months of runway | 8.0 |
| Days since last periodic filing | 88 (10-Q received Aug 5, 2026) |
| Median daily dollar volume, 63 sessions | $234,958 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$1.1B | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$897.7M | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 3 | assets | us-gaap:Assets | $2.4B | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 4 | assets | us-gaap:Assets | $2.6B | 2024-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 5 | current assets | us-gaap:AssetsCurrent | $2.1B | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $290.4M | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$2.9B | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$1.2B | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 9 | book equity | us-gaap:StockholdersEquity | $1.6B | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 10 | liabilities | us-gaap:Liabilities | $723.2M | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$258.3M | 2022-12-31 | 2025-02-26 | 10-K | 25-027736 |
| 12 | interest expense | us-gaap:InterestExpense | $0 | 2022-12-31 | 2023-02-27 | 10-K | 23-004645 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $0 | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $0 | 2024-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $11.6M | 2023-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $35.4M | 2022-12-31 | 2025-02-26 | 10-K | 25-027736 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $16.0M | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$557.4M | 2024-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $10.3M | 2024-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$350.6M | 2023-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $7.7M | 2023-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$224.4M | 2022-12-31 | 2025-02-26 | 10-K | 25-027736 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $10.8M | 2022-12-31 | 2025-02-26 | 10-K | 25-027736 |
| 24 | depreciation amortization | us-gaap:Depreciation | $7.4M | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 25 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$1.1B | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 26 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 27 | current assets | us-gaap:AssetsCurrent | $2.3B | 2024-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 28 | current liabilities | us-gaap:LiabilitiesCurrent | $163.9M | 2024-12-31 | 2026-02-25 | 10-K | 26-071563 |
| 29 | assets | us-gaap:Assets | $2.1B | 2023-12-31 | 2025-02-26 | 10-K | 25-027736 |
| 30 | assets | us-gaap:Assets | $811.9M | 2022-12-31 | 2024-02-26 | 10-K | 24-020145 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.